Abstract 68P
Background
The growth rate of this indicator compared to 2020 was 16.4%, and among the female population: breast cancer (24.0), cervical cancer (10.6), and ovarian cancer (5.7 per 100,000 population). The incidence of ovarian cancer (RY) throughout the world and in Uzbekistan tends to constantly increase. In Uzbekistan, the incidence was 5.7 per 100,000 population in 2021; in 2015, this figure was 4.7.
Methods
The object of the study was 116 female patients with a verified diagnosis of ovarian cancer complicated by ascites (OCA) who were treated at the Russian National Medical Research Center for Medical and Radiological Research as well as at the Samarkand branch from 2017 to 2023. Patients were randomized as follows: Group 1 received standard palliative therapy: gemcitabine 1000 mg/m2 on days 1, 8, 15, and bevacizumab at a dose of 7.5–15 mg/kg once every 3 weeks (n = 42); Group 2 patients receiving metronomic chemotherapy:cyclophosphamide 50 mg/day orally daily without a break (n = 33); and Group 3 patients receiving metronomic chemotherapy: cyclophosphamide 50 mg/day. orally daily without interruption, and pazopanib 400 mg days 1–28 (n = 41).
Results
Please see the table below.Table: 68P
| Study Groups | |||||||||
| Group 1, n=42 | Group 2, n=33 | Group 3, n=41 | |||||||
| abs | M (%) | m | abs | M (%) | m | abs | M (%) | m | |
| Full effect | 0 | 0.00 | 0.00 | 0 | 0.00 | 0.00 | 0 | 0.00 | 0.00 |
| Partial effect | 14 | 33.33 | 7.27 | 14 | 42.42 | 8.60 | 18 | 43.90 | 7.75 |
| Stabilization | 10 | 23.81 | 5.57 | 10 | 30.30 | 8.00 | 14 | 35.15* | 4.41 |
| Progression | 18 | 42.86 | 7.64 | 9 | 27.27* | 7.75 | 9 | 21.95* | 6.4 |
Conclusions
Was developed a new method of metronomic maintenance chemotherapy, which is the use of cyclophosphamide and pazopanib in low doses in patients with ascites caused by platinum-resistant recurrent ovarian cancer after completion of second-line chemotherapy. This method helps to achieve disease control in 65.7% of patients and increase the median time to progression from 7.4 to 9.1 months. (plog-rank <0.0001), median overall survival observed from 15.0 to 22.7 months. (plog-rank = 0.0005).
Legal entity responsible for the study
Samarkand State Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.